Table of Contents
SERIES 7 | SERIES 65 | FINANCIAL REGULATION COURSES
FINRA Rule 2241 — Research Analysts and Research Reports — is the comprehensive principles-based rule governing the preparation, publication, and distribution of equity research reports by FINRA member firms, requiring firms to establish written policies and procedures that identify and manage conflicts of interest between their research and investment banking functions, prohibiting investment banking personnel from influencing research content, restricting analyst compensation tied to investment banking revenues, imposing quiet periods following public offerings, and mandating comprehensive conflict of interest disclosures in every research report — protecting the integrity of equity research as an independent source of investment analysis for investors who rely on it in making securities decisions.
Rule 2241 was adopted by FINRA and approved by the Securities and Exchange Commission in July 2015, effective December 24, 2015 — replacing the prior NASD Rule 2711 and NYSE Rule 472 that had governed equity research conflicts since their adoption in the aftermath of the dot-com era research analyst scandals of the late 1990s and early 2000s. The Global Research Analyst Settlement of 2003 — the landmark enforcement action against ten major Wall Street firms for research analyst conflicts — had imposed rigid structural safeguards including mandatory information barriers and independent research funding requirements that remained in effect for more than two decades alongside the FINRA rulebook framework. The SEC formally retired the remaining undertakings of the Global Research Settlement in December 2025, leaving Rule 2241 as the primary regulatory framework governing equity research conflicts.
For every registered representative who receives, reads, and relies on equity research reports in serving customers — and for every research analyst whose work is governed by the rule — understanding the conflicts that Rule 2241 addresses, the structural protections it requires, and the disclosures it mandates is foundational professional knowledge tested on the Series 7 examination.
The regulatory framework governing equity research conflicts has its origins in the spectacular collapse of public confidence in Wall Street research during the dot-com bubble and its aftermath — when it became clear that research analysts at major investment banks had been publicly recommending stocks to retail investors while privately describing those same stocks in far less flattering terms, motivated by the enormous investment banking fees their firms stood to earn from the companies being recommended.
The most notorious cases — involving analysts at Merrill Lynch, Citigroup, and other major broker-dealers — revealed a systematic pattern in which investment banking considerations had corrupted the research function. Analysts whose compensation was tied to the investment banking revenues generated by covered companies had powerful financial incentives to issue and maintain favourable ratings regardless of their genuine assessment of the companies' investment merit. Research reports that investors relied on as independent professional analysis were in practice marketing documents designed to support the firm's investment banking relationships.
The Sarbanes-Oxley Act of 2002 addressed equity research conflicts at the statutory level — directing FINRA and the SEC to adopt rules establishing standards of conduct for research analysts. The Global Research Settlement imposed specific structural requirements including mandatory information barriers between research and investment banking, independent research funding requirements, and restrictions on analyst compensation. FINRA Rule 2241 consolidated and modernised these requirements into a principles-based framework that gives firms flexibility in designing their specific compliance programmes while maintaining the core structural protections that the research analyst scandals demonstrated were necessary.
The foundational requirement of Rule 2241 is the obligation for every FINRA member firm that publishes equity research reports to establish, maintain, and enforce written policies and procedures reasonably designed to identify and effectively manage conflicts of interest related to the preparation, content, and distribution of research reports and public appearances by research analysts.
These policies and procedures must address the full range of potential conflicts — separating research from investment banking with respect to the supervision of research analysts, the determination of research budgets, and the compensation of analysts. The supervision separation requirement prohibits investment banking personnel from having any supervisory authority over research analysts — ensuring that the people responsible for generating investment banking revenues cannot direct the content or coverage decisions of the research function.
The budget separation requirement prohibits research budgets from being determined by the investment banking department or by reference to specific investment banking transactions — preventing the indirect influence of investment banking considerations on the research function through resource allocation decisions.
The information barrier requirement — one of the most important structural protections — requires firms to establish barriers or other institutional safeguards reasonably designed to insulate research analysts from investment banking personnel and from others whose interests might compromise research objectivity. Information barriers prevent investment bankers from communicating their coverage preferences, transaction-related sensitivities, or client relationship considerations to research analysts in ways that could influence research content.
Rule 2241 imposes specific restrictions on research analyst compensation — the dimension of the research analyst conflict that was most directly implicated in the dot-com era scandals where analysts' bonus compensation was explicitly linked to investment banking revenues from companies they covered.
The rule prohibits any member of the investment banking department from having any input into the compensation of a research analyst — and prohibits research analyst compensation from being determined or evaluated on the basis of contributions to specific investment banking transactions. The connection between investment banking deal flow and research analyst compensation is the mechanism that creates the most direct financial incentive for analysts to issue favourable ratings — and Rule 2241 severs this connection categorically.
Research analyst compensation may be based on the quality and accuracy of research, investor feedback, the analyst's overall contribution to the firm's research function, and general measures of firm profitability that are not tied to specific investment banking transactions. What it may not be based on is the volume of investment banking business generated by companies the analyst covers or the analyst's contributions to soliciting investment banking business.
For member firms with limited investment banking activity — defined as firms that over the preceding three years participated on average in ten or fewer investment banking transactions as manager or co-manager and generated five million dollars or less in gross revenue from those transactions — Rule 2241 permits investment bankers to participate on the research compensation committee, acknowledging that the strict structural separation requirements designed for large full-service investment banks may be disproportionately burdensome for smaller firms with limited investment banking operations.
Rule 2241 identifies specific categories of conduct that are categorically prohibited because they represent the most direct forms of investment banking interference with research independence.
Promises of favourable research — offering or promising a specific research rating, coverage initiation, or favourable research outcome to any company in connection with obtaining investment banking business from that company — are absolutely prohibited. The quid pro quo of favourable research for investment banking business is the clearest form of research corruption and the practice most directly implicated in the dot-com era enforcement actions.
Investment banking solicitation — having a research analyst participate in investment banking solicitation activities or road shows in a manner that suggests to potential clients that research coverage or ratings are contingent on the investment banking relationship — is prohibited. A research analyst may attend a road show in a purely informational capacity, but may not be presented to potential investment banking clients as an incentive to award the firm banking business based on the prospect of favourable research.
Pre-publication review by investment banking — allowing investment banking personnel, subject company management, or other parties with conflicting interests to review or approve research reports before publication — is prohibited except in the limited context of factual verification of information in the research report. The prohibition on pre-publication review by interested parties ensures that the research content reflects the analyst's genuine professional judgment rather than a negotiated outcome shaped by parties with financial interests in the research conclusions.
Rule 2241 imposes quiet periods — restrictions on the publication of research reports about companies following their involvement in public securities offerings — that prevent member firms from using research reports as promotional tools immediately following transactions in which they served as underwriters.
Following an initial public offering in which the member firm served as a manager or co-manager — one of the lead underwriters of the transaction — a ten-day quiet period prohibits the publication of research on the newly public company. This ten-day quiet period replaced the prior forty-day quiet period that had applied under the predecessor rules — reflecting the regulatory judgment that a shorter but still meaningful quiet period better balances investor protection against the practical need for research coverage of newly public companies.
For syndicate members — firms that participated in the offering as selling group members but not as lead underwriters — the same ten-day quiet period applies following initial public offerings.
Following secondary offerings — additional equity offerings by companies that are already publicly traded — a three-day quiet period applies for managers and co-managers, while syndicate members not serving as managers or co-managers face no quiet period requirement. The shorter quiet period for secondary offerings reflects the reduced concern about research being used to support initial price discovery for already-public companies whose trading history provides investors with substantial additional valuation information.
Every equity research report published by a FINRA member firm must include specific disclosures about conflicts of interest that may affect the objectivity and reliability of the research — giving investors the information they need to evaluate the research in light of the analyst's and firm's potential financial interests.
Required disclosures include whether the member firm or any of its affiliates managed or co-managed a public offering of the subject company's securities within the preceding twelve months — alerting investors to the investment banking relationship that may have created the most direct conflict of interest. The disclosure of whether the member firm received or expects to receive compensation for investment banking services from the subject company within the next three months ensures that investors are aware of prospective as well as recent banking relationships.
The research report must disclose whether the member firm or any of its affiliates owns one percent or more of any class of the subject company's equity securities — a significant financial interest that could influence the analyst's objectivity. Analyst ownership of the subject company's securities — held personally by the analyst or a member of their household — must be disclosed, as must any other material conflict of interest of which the firm or analyst is aware.
The distribution of ratings across all securities covered by the member firm's research department — the percentage of covered companies rated buy, hold, and sell — must be disclosed to give investors context for interpreting the specific rating assigned to the subject company. This distribution disclosure addresses the historical pattern of rating inflation in which analysts issued far more buy recommendations than hold or sell recommendations — making the overall rating distribution visible to investors who might otherwise assume that a buy rating represents an above-average assessment when it is in fact the norm.
Rule 2241 operates within the broader historical context of the Global Research Settlement — the landmark 2003 enforcement action against Citigroup, Merrill Lynch, Goldman Sachs, Morgan Stanley, and six other major broker-dealers that resulted in payments of approximately one point four billion dollars and the imposition of structural requirements designed to restore research independence following the dot-com era scandals.
The Global Research Settlement's structural requirements — mandatory information barriers, independent research funding, physical separation of research and investment banking — operated alongside the FINRA rulebook framework for more than two decades. The SEC's retirement of the Settlement undertakings in December 2025 marked the formal conclusion of the settlement's supervisory oversight — leaving FINRA Rule 2241's principles-based framework as the primary regulatory structure governing equity research conflicts.
The transition from the rigid structural requirements of the Settlement to the principles-based framework of Rule 2241 reflects FINRA's broader regulatory philosophy of allowing firms to design compliance programmes tailored to their specific business models and risk profiles — while maintaining the core prohibitions and disclosure requirements that are necessary to protect the integrity of equity research regardless of firm-specific circumstances.
FINRA Rule 2241 is tested on the Series 7 examination in the context of research analyst conflicts of interest, the structural separation of research from investment banking, compensation restrictions, quiet periods, and required research report disclosures.
The key points to retain are these.
FINRA Rule 2241 — Research Analysts and Research Reports — governs conflicts of interest in equity research, requiring firms to establish written policies and procedures identifying and managing research-related conflicts. The rule separates research from investment banking through supervision separation — investment banking personnel may not supervise research analysts — budget separation — research budgets may not be determined by the investment banking department — and information barriers preventing investment banking considerations from influencing research content.
Research analyst compensation may not be tied to specific investment banking transactions or contributions to investment banking revenues. Categorical prohibitions include promises of favourable research in connection with investment banking business, research analyst participation in solicitation activities that suggest research coverage is tied to banking relationships, and pre-publication review of research by investment banking personnel or subject company management beyond factual verification. Quiet periods following initial public offerings are ten days for both managers and syndicate members — replacing the prior forty-day period. Quiet periods following secondary offerings are three days for managers and co-managers with no requirement for other syndicate members.
Required research report disclosures include investment banking relationships within the preceding twelve months and prospective banking compensation, firm ownership of one percent or more of the subject company's equity, analyst personal ownership of the subject company's securities, and the distribution of ratings across all covered companies. The SEC retired the Global Research Settlement undertakings in December 2025 — leaving Rule 2241 as the primary equity research conflict of interest framework.
